keyword
MENU ▼
Read by QxMD icon Read
search

Ocular melanoma

keyword
https://www.readbyqxmd.com/read/28730794/athens-eye-hospital-ocular-oncology-multidisciplinary-team-providing-combined-treatments-for-patients-with-choroidal-melanoma-3-years-results
#1
Anastasios Anastasakis, Panagiotis Zafeirakis, Charalampos Livir-Rallatos, Gerasimos Livir-Rallatos
No abstract text is available yet for this article.
May 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28730793/athens-eye-hospital-ocular-oncology-multidisciplinary-team-providing-combined-treatments-for-patients-with-choroidal-melanoma-3-years-results
#2
Anastasios Anastasakis, Panagiotis Zafeirakis, Charalampos Livir-Rallatos, Gerasimos Livir-Rallatos, Mutlu Hayran
No abstract text is available yet for this article.
May 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28728906/surgical-management-of-strabismus-following-choroidal-melanoma-plaque-brachytherapy
#3
Shatha H Alfreihi, Stacy L Pineles, Tara A McCannel, Angelica M Prada, Federico G Velez
PURPOSE: To characterize intraoperative findings, surgical approach, and postoperative outcomes in patients undergoing strabismus surgery following plaque brachytherapy for ocular melanoma. METHODS: The records of all patients who underwent plaque brachytherapy for choroidal melanoma between May 2007 and June 2016 were reviewed retrospectively to identify those who subsequently required strabismus surgery. RESULTS: Of the 461 patients who underwent plaque brachytherapy during the study period, 13 (2...
July 17, 2017: Journal of AAPOS: the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus
https://www.readbyqxmd.com/read/28719046/retinal-pigment-epithelium-adenoma-in-vitreous-fluid-cytology
#4
Sandhya John, Madelyn Lew
Ocular cytology specimens are relatively uncommon, adding to the difficulty of their evaluation by cytopathologists. While melanomas account for a majority of primary intraocular pigmented lesions, other diagnostic considerations must be included in the differential. This brief report highlights a case of a pigmented ocular lesion in a 24-year-old man and key morphologic, immunohistochemical, and clinical differences between melanoma, melanocytoma, choroidal nevus, and retinal pigment epithelium (RPE) adenoma...
July 18, 2017: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/28690979/presentation-treatment-and-prognosis-of-secondary-melanoma-within-the-orbit
#5
Anna M Rose, Sophie Cowen, Channa N Jayasena, David H Verity, Geoffrey E Rose
BACKGROUND: Ocular melanoma is a rare but often deadly malignancy that arises in the uvea, conjunctiva, or orbit. Uveal melanoma is the most common type, with conjunctival melanoma being the second most frequently observed. Melanoma accounts for 5-10% of metastatic or secondary orbital malignancies, but only a minute proportion of primary orbital neoplasia. The aim of this study was to characterize the clinical presentation, treatment, and prognosis in patients presenting with melanoma metastatic to, or secondary within, the orbit...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28688464/parkinson-disease-and-melanoma-confirming-and-reexamining-an-association
#6
Lauren A Dalvin, Gena M Damento, Barbara P Yawn, Barbara A Abbott, David O Hodge, Jose S Pulido
OBJECTIVE: To examine an association between melanoma and Parkinson disease (PD). PATIENTS AND METHODS: Phase I: Rochester Epidemiology Project records were used to identify (between January 1, 1976, and December 31, 2013) patients with PD in Olmsted County, Minnesota, with 3 matched controls per case. After review, JMP statistical software with logistic regression analysis was used to assess the risk of preexisting melanoma in patients with PD vs controls. Phase II: All Rochester Epidemiology Project cases of melanoma were identified (between January 1, 1976, and December 31, 2014), with 1 control per case...
July 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/28685998/iridociliary-cysts-masquerading-as-neoplasia-in-cats-a-morphologic-review-of-14-cases
#7
Jessica A Fragola, Richard R Dubielzig, Ellison Bentley, Leandro B C Teixeira
OBJECTIVE: To report 14 neoplasia-free feline eyes enucleated for suspected intraocular neoplasia containing only iridociliary cysts. To analyze clinical findings that may have led veterinarians to suspect neoplasia in these globes. PROCEDURES: The archives at the Comparative Ocular Pathology Laboratory of Wisconsin (COPLOW) were searched to identify neoplasia-free feline globes enucleated for suspected neoplasia. Clinical data were obtained from medical records, veterinarian surveys, and COPLOW submission forms...
July 6, 2017: Veterinary Ophthalmology
https://www.readbyqxmd.com/read/28662141/sdhd-promoter-mutations-are-rare-events-in-cutaneous-melanomas-but-sdhd-protein-expression-is-downregulated-in-advanced-cutaneous-melanoma
#8
Helena Pópulo, Rui Batista, Cristina Sampaio, Joana Pardal, José Manuel Lopes, Paula Soares
BACKGROUND: SDHD promoter mutations were reported in 4-10% of cutaneous melanomas. The advanced clinico-pathological and patient survival association with SDHD mutation and/or expression in cutaneous melanoma remains controversial. OBJECTIVES: To evaluate the presence of SDHD promoter mutations and SDHD protein expression in a melanoma series and its possible association with prognosis and survival of the patients. METHODS: We assessed SDHD promoter status in cutaneous melanomas (CM), ocular melanomas (OM) and melanoma cell lines, and the expression of SDHD protein by immunohistochemistry in CM and OM, and by western blot in melanoma cell lines...
2017: PloS One
https://www.readbyqxmd.com/read/28648699/prognostic-factors-and-outcomes-in-metastatic-uveal-melanoma-treated-with-programmed-cell-death-1-or-combined-pd-1-cytotoxic-t-lymphocyte-antigen-4-inhibition
#9
Markus V Heppt, Lucie Heinzerling, Katharina C Kähler, Andrea Forschner, Michael C Kirchberger, Carmen Loquai, Markus Meissner, Friedegund Meier, Patrick Terheyden, Beatrice Schell, Rudolf Herbst, Daniela Göppner, Felix Kiecker, David Rafei-Shamsabadi, Sebastian Haferkamp, Margit A Huber, Jochen Utikal, Mirjana Ziemer, Irmgard Bumeder, Christiane Pfeiffer, Susanne G Schäd, Christoph Schmid-Tannwald, Julia K Tietze, Thomas K Eigentler, Carola Berking
BACKGROUND: Uveal melanoma (UM) is an ocular malignancy with high potential for metastatic spread. In contrast to cutaneous melanoma, immunotherapy has not yet shown convincing efficacy in patients with UM. Combined immune checkpoint blockade with checkpoint programmed cell death-1 (PD-1) and checkpoint cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibition has not been systematically assessed for UM to date. PATIENTS AND METHODS: Patients with metastatic UM treated with either PD-1 inhibitor monotherapy or combined PD-1 inhibitor and ipilimumab (an anti-CTLA-4 monoclonal antibody) were included from 20 German skin cancer centres...
June 21, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28646893/clinical-features-of-serous-retinopathy-observed-with-cobimetinib-in-patients-with-braf-mutated-melanoma-treated-in-the-randomized-cobrim-study
#10
Luis de la Cruz-Merino, Lorenza Di Guardo, Jean-Jacques Grob, Alfredo Venosa, James Larkin, Grant A McArthur, Antoni Ribas, Paolo A Ascierto, Jeffrey T R Evans, Antonio Gomez-Escobar, Giulio Barteselli, Susan Eng, Jessie J Hsu, Anne Uyei, Brigitte Dréno
BACKGROUND: Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF (V600)-mutated melanoma treated in the Phase III coBRIM study. METHODS: In the coBRIM study, 493 patients were treated in two randomly assigned treatment groups: cobimetinib and vemurafenib (n = 247) or vemurafenib (n = 246). All patients underwent prospective ophthalmic examinations at screening, at regular intervals during the study, and whenever ocular symptoms developed...
June 24, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28640512/a-major-responder-to-ipilimumab-and-nivolumab-in-metastatic-uveal-melanoma-with-concomitant-autoimmunity
#11
Pui Ying Chan, Peter Hall, Gordon Hay, Victoria M L Cohen, Peter W Szlosarek
The use of immune checkpoint inhibition has led to major improvements in outcome for patients with metastatic cutaneous melanoma. The combination of ipilimumab and nivolumab has demonstrated greater activity over single agent immunotherapy in phase III trials. Clinical trials of combination CTLA-4 and PD-1 inhibition are underway in uveal melanoma, for which there are currently no data. Here, we present the case of a 74-year-old male patient with metastatic uveal melanoma, who was treated with a combination of ipilimumab and nivolumab...
June 22, 2017: Pigment Cell & Melanoma Research
https://www.readbyqxmd.com/read/28634727/safety-and-efficacy-of-chemosaturation-in-patients-with-primary-and-secondary-liver-tumors
#12
Martha M Kirstein, Steffen Marquardt, Nils Jedicke, Silke Marhenke, Wolfgang Koppert, Michael P Manns, Frank Wacker, Arndt Vogel
BACKGROUND: Chemosaturation with percutaneous hepatic perfusion (CS-PHP; hepatic CHEMOSAT(®) delivery system; Delcath Systems Inc, USA) is a novel medical device, which delivers high doses of melphalan directly to the liver in patients with primary and secondary liver tumors while limiting systemic toxicity through hemofiltration of the hepatic venous blood. The aim of this study was to analyze the safety and efficacy of the second-generation CS-PHP after 54 treatments at Hannover Medical School, Germany...
June 20, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28626853/conjunctival-melanoma-in-southwestern-nigeria-a-case-series-and-review-of-literature
#13
Oluyemi Fasina, Olayiwola A Oluwasola
PURPOSE: Conjunctival melanoma is a rare tumor worldwide and is extremely rare among black population. This study aims to report the demographics, clinical presentation, treatment, and outcome of patients seen in an indigenous black population in Southwestern Nigeria. METHODS: All patients histologically diagnosed with conjunctival melanoma and managed in the facility were reviewed. Their demographics, clinical presentation, treatment received, outcome of treatment, and histopathological features were analyzed...
June 19, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28624008/a-systematic-review-of-yttrium-90-radioembolization-for-unresectable-liver-metastases-of-melanoma
#14
REVIEW
Zhongzhi Jia, Guomin Jiang, Chunfu Zhu, Kai Wang, Shaoqin Li, Xihu Qin
PURPOSE: To assess the effectiveness of yttrium-90 ((90)Y) radioembolization in the treatment of unresectable liver metastases of melanoma. METHODS: PubMed and EMBASE were systemically searched for all English language studies related to (90)Y radioembolization for unresectable liver metastases of melanoma, including clinical trials, observational studies, and abstracts from conferences, published between January 1991 and March 2016. RESULTS: A total of 12 reports (7 observational studies and 5 abstracts from conferences) involving 255 patients were included in the analysis...
July 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28613357/optical-coherence-tomography-angiography-in-the-multimodal-imaging-evaluation-of-interferon-associated-retinopathy-a-case-report
#15
Leonardo Mastropasqua, Enrico Borrelli, Francesco Amodei, Agbeanda Aharrh-Gnama, Lisa Toto, Peter A Mattei, Rodolfo Mastropasqua
The authors present the case of a 59-year-old woman in treatment with interferon alfa-2b for stage IV melanoma and widespread metastases who presented with interferon-associated retinopathy. An ocular examination revealed multiple retinal cotton-wool spots and hard exudates. Interferon treatment was suspended. The patient was followed up for 5 months following the baseline visit by means of en face optical coherence tomography (OCT), spectral-domain OCT, and OCT angiography. Multimodal imaging was useful in the follow-up of this condition, permitting the characterization of all the lesions hallmarking the interferon-retinopathy and showing that this illness was related to a reduction of the retinal vascular perfusion...
June 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28604554/severe-ocular-myositis-after-ipilimumab-treatment-for-melanoma-a-report-of-2-cases
#16
Anna Pushkarevskaya, Ulf Neuberger, Antonia Dimitrakopoulou-Strauss, Alexander Enk, Jessica C Hassel
Ipilimumab binds and blocks cytotoxic T-lymphocyte-associated antigen-4, causing enhanced T-cell reaction, antitumor response, and significant improvement of the overall survival of patients with metastatic melanoma. Patients treated with ipilimumab can develop immune-related adverse effects, primarily dermatitis, colitis, hepatitis, and hypophysitis. Although, in phase I-III studies, 64.2% of all patients suffered from immune-related adverse effects, ocular adverse effects occurred in 1.3% only. In the cases reported below, 2 patients with metastatic melanoma developed severe ocular myositis after treatment with ipilimumab...
June 9, 2017: Journal of Immunotherapy
https://www.readbyqxmd.com/read/28599417/overexpression-of-the-anti-apoptotic-protein-bag3-in-human-choroidal-melanoma-a-case-report
#17
Tatsuya Yunoki, Yoshiaki Tabuchi, Takashi Kondo, Yoko Ishii, Atsushi Hayashi
Bcl-2-associated athanogene 3 (BAG3), a co-chaperone of heat shock protein 70 (HSP70), exerts anti-apoptotic effects in various malignant tumors. However, relationships between choroidal melanoma and BAG3 are poorly studied. This study investigated the expression of BAG3 in a case of human choroidal melanoma. Funduscopy, computed tomography, and single-photon emission computed tomography with the intravenous injection of N-isopropyl-p-[(123)I] iodoamphetamine strongly indicated choroidal melanoma in a 68-year-old woman...
June 2017: Oncology Letters
https://www.readbyqxmd.com/read/28595565/gold-nanoparticles-by-laser-ablation-for-x-ray-imaging-and-protontherapy-improvements
#18
Torrisi Lorenzo, Nancy Restuccia, Irene Paterniti
Gold nanoparticles, 5-20 nm in diameter, were generated with a pulsed Nd:YAG laser at 1010 W/cm2 at solution concentrations ranging between 1-100 mg/ml. Nanoparticles were characterized using optical absorbance, X-ray fluorescence, SEM, and TEM. Biocompatible nanoparticle solutions were injected by intravenously into the tail veins of mice followed by X-ray imaging using 20-45 keV photons to evaluate the uptake and the clearance by different organs of the nanoparticles. The incremental X-ray contrast imaging using gold nanoparticles was investigated and measured...
June 8, 2017: Recent Patents on Nanotechnology
https://www.readbyqxmd.com/read/28586956/stereotactic-radiosurgery-and-fractionated-stereotactic-radiation-therapy-for-the-treatment-of-uveal-melanoma
#19
Gozde Yazici, Hayyam Kiratli, Gokhan Ozyigit, Sezin Yuce Sari, Mustafa Cengiz, Bercin Tarlan, Burce Ozgen Mocan, Faruk Zorlu
PURPOSE: To evaluate treatment results of stereotactic radiosurgery or fractionated stereotactic radiation therapy (SRS/FSRT) for uveal melanoma. METHODS AND MATERIALS: We retrospectively evaluated 181 patients with 182 uveal melanomas receiving SRS/FSRT between 2007 and 2013. Treatment was administered with CyberKnife. RESULTS: According to Collaborative Ocular Melanoma Study criteria, tumor size was small in 1%, medium in 49.5%, and large in 49...
May 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28586953/dry-eye-syndrome-after-proton-therapy-of-ocular-melanomas
#20
Juliette Thariat, Celia Maschi, Sara Lanteri, Marie Laure Peyrichon, Stephanie Baillif, Joel Herault, Julia Salleron, Jean Pierre Caujolle
PURPOSE: To investigate whether proton therapy (PT) performs safely in superotemporal melanomas, in terms of risk of dry-eye syndrome (DES). METHODS AND MATERIALS: Tumor location, DES grade, and dose to ocular structures were analyzed in patients undergoing PT (2005-2015) with 52 Gy (prescribed dose, not accounting for biologic effectiveness correction of 1.1). Prognostic factors of DES and severe DES (sDES, grades 2-3) were determined with Cox proportional hazard models...
May 1, 2017: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
35917
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"